The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases
Open accessAbstract
In the last 10 years, we have learned much about the pathogenesis, diagnosis, and management of intestinal fibrosis in patients with inflammatory bowel diseases (IBD). Just a decade ago, intestinal strictures were considered to be an inevitable consequence of long-term inflammation in patients who did not respond to anti-inflammatory therapies. IBD-associated fibrosis was seen as an irreversible process that frequently led to intestinal obstructions requiring surgical intervention. This paradigm has changed rapidly, due to the anti-fibrotic approaches that may become available. We review the mechanisms and diagnosis of this serious complication of IBD, as well as factors that predict its progression and management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Predictability of the postoperative course of Crohn's disease
Rutgeerts, P., Geboes, K., Vantrappen, G., Beyls, J., Kerremans, R., & Hiele, M. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90613-6 · Cited by 1,820
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., et al. (2004) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)01878-4 · Cited by 1,774
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Long-Term Evolution of Disease Behavior of Crohn's Disease
Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R., & Gendre, J.-P. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00002 · Cited by 1,346
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Gasche, C., Scholmerich, J., Brynskov, J., DʼHaens, G., Hanauer, S. B., Irvine, J. E., Jewell, D. P., Rachmilewitz, D., Sachar, D. B., Sandborn, W. J., et al. (2000) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200002000-00002 · Cited by 1,134
The role of matrix stiffness in regulating cell behavior†
Wells, R. G. (2008) · Hepatology · doi:10.1002/hep.22193 · Cited by 1,059
Cited by
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Self-citationCytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750
Bettenworth, D., Bokemeyer, A., Baker, M., Mao, R., Parker, C. E., Nguyen, T., Ma, C., Panés, J., Rimola, J., Fletcher, J. G., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318081 · Cited by 306
Self-citationTGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
Rieder, F., Bettenworth, D., Ma, C., Parker, C. E., Williamson, L. A., Nelson, S. A., van Assche, G., Di Sabatino, A., Bouhnik, Y., Stidham, R. W., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14853 · Cited by 264
Self-citationRevisiting fibrosis in inflammatory bowel disease: the gut thickens
D’Alessio, S., Ungaro, F., Noviello, D., Lovisa, S., Peyrin-Biroulet, L., & Danese, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00543-0 · Cited by 253
Flagellin-mediated activation of IL-33-ST2 signaling by a pathobiont promotes intestinal fibrosis
Imai, J., Kitamoto, S., Sugihara, K., Nagao-Kitamoto, H., Hayashi, A., Morhardt, T. L., Kuffa, P., Higgins, P. D. R., Barnich, N., & Kamada, N. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0138-4 · Cited by 91
Wang, M., Zhou, B., Cong, W., Zhang, M., Li, Z., Li, Y., Liang, S., Chen, K., Yang, D., & Wu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797605 · Cited by 71
Zhao, S., Dejanovic, D., Yao, P., Bhilocha, S., Sadler, T., Schirbel, A., West, G., Doyon, G., Lopez, R., Mao, R., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0259-9 · Cited by 59
Self-citationModelling and targeting mechanical forces in organ fibrosis
Mascharak, S., L. Guo, J., Griffin, M., E. Berry, C., C. Wan, D., & T. Longaker, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00144-3 · Cited by 59
“Similar processes of ECM compositional change and connective tissue thickening have been implicated in the pathogenesis of intestinal fibrosis, including similar feedforward loops for myofibroblasts 30,31 .”
Metadata
- Authors
- Rieder, F., Fiocchi, C., & Rogler, G.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 152
- Issue
- 2
- Pages
- 340-350.e6
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2529401211
- Cited by
- 529
- References
- 152
- FWCI
- 22.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.